• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
FDA greenlights momelotinib (Ojjaara) as the exclusive treatment for myelofibrosis patients battling anemia.美国食品药品监督管理局（FDA）批准 momelotinib（Ojjaara）作为治疗患有贫血症的骨髓纤维化患者的唯一疗法。
Ann Med Surg (Lond). 2024 Oct 23;86(12):6916-6917. doi: 10.1097/MS9.0000000000002690. eCollection 2024 Dec.
2
Momelotinib: First Approval.莫雷洛替尼：首次获批。
Drugs. 2023 Dec;83(18):1709-1715. doi: 10.1007/s40265-023-01964-8.
3
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.莫米松替比 versus 持续芦可替尼或 JAK 抑制剂治疗经验的骨髓纤维化伴贫血患者的最佳可用治疗：SIMPLIFY-2 的亚组分析。
Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11.
4
Momelotinib for the treatment of myelofibrosis with anemia.莫雷洛替尼治疗伴贫血的骨髓纤维化。
Future Oncol. 2022 Jun;18(20):2559-2571. doi: 10.2217/fon-2022-0276. Epub 2022 May 23.
5
Momelotinib: an emerging treatment for myelofibrosis patients with anemia.莫雷洛替尼：治疗贫血性骨髓纤维化患者的新兴疗法。
J Hematol Oncol. 2022 Jan 19;15(1):7. doi: 10.1186/s13045-021-01157-4.
6
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.从 MOMENTUM 研究看芦可替尼对比达那唑治疗骨髓纤维化患者的输血相关费用节省和时间负担
Future Oncol. 2024;20(30):2259-2270. doi: 10.1080/14796694.2024.2368450. Epub 2024 Jul 29.
7
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.骨髓纤维化中的贫血：关注积极管理及莫洛替尼的作用
Cancers (Basel). 2024 Dec 4;16(23):4064. doi: 10.3390/cancers16234064.
8
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
9
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.莫洛替尼与达那唑治疗 JAK 抑制剂预处理的有症状贫血和骨髓纤维化患者（MOMENTUM）：一项国际、双盲、随机 3 期研究的更新分析。
Lancet Haematol. 2023 Sep;10(9):e735-e746. doi: 10.1016/S2352-3026(23)00174-6. Epub 2023 Jul 27.
10
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.SIMPLIFY-1 和 SIMPLIFY-2 期临床试验中，芦可替尼治疗骨髓纤维化患者的总生存情况。
Leukemia. 2022 Sep;36(9):2261-2268. doi: 10.1038/s41375-022-01637-7. Epub 2022 Jul 22.

本文引用的文献

1
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.莫米松（JAK1/JAK2/ACVR1 抑制剂）：作用机制、临床试验报告以及除骨髓纤维化之外的治疗前景。
Haematologica. 2023 Nov 1;108(11):2919-2932. doi: 10.3324/haematol.2022.282612.
2
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.原发性骨髓纤维化：2023年诊断、风险分层及管理的最新进展
Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6.
3
Induced Mitochondrial Alteration and DNA Damage via IFNGR-JAK2-STAT1-PARP1 Pathway Facilitates Viral Hepatitis Associated Hepatocellular Carcinoma Aggressiveness and Stemness.通过IFNGR-JAK2-STAT1-PARP1途径诱导的线粒体改变和DNA损伤促进病毒性肝炎相关肝细胞癌的侵袭性和干性。
Cancers (Basel). 2021 Jun 2;13(11):2755. doi: 10.3390/cancers13112755.
4
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.ACVR1/JAK1/JAK2 抑制剂 momelotinib 逆转骨髓纤维化 2 期试验中的输血依赖并抑制铁调素。
Blood Adv. 2020 Sep 22;4(18):4282-4291. doi: 10.1182/bloodadvances.2020002662.
5
Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.莫洛替尼通过抑制 JAK2/STAT3 增强自噬作用使胶质母细胞瘤细胞对替莫唑胺敏感。
Oncol Rep. 2019 Mar;41(3):1883-1892. doi: 10.3892/or.2019.6970. Epub 2019 Jan 16.
6
Momelotinib therapy for myelofibrosis: a 7-year follow-up.莫雷洛替尼治疗骨髓纤维化：7 年随访结果。
Blood Cancer J. 2018 Mar 7;8(3):29. doi: 10.1038/s41408-018-0067-6.
7
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.Momelotinib对比最佳可用疗法治疗既往接受过鲁索替尼治疗的骨髓纤维化患者（SIMPLIFY 2）：一项随机、开放标签的3期试验
Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.
8
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.SIMPLIFY-1：一项在初治的骨髓纤维化患者中比较莫洛替尼与芦可替尼的III期随机试验。
J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.
9
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.泊马度胺对比安慰剂治疗骨髓增殖性肿瘤相关骨髓纤维化且依赖红细胞输血患者的随机研究。
Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24.
10
Risk factors for leukemic transformation in patients with primary myelofibrosis.原发性骨髓纤维化患者白血病转化的危险因素。
Cancer. 2008 Jun 15;112(12):2726-32. doi: 10.1002/cncr.23505.

FDA greenlights momelotinib (Ojjaara) as the exclusive treatment for myelofibrosis patients battling anemia.

作者信息

Jehanzeb Memuna, Iqbal Urooj, Farhat Neha, Waseem Radeyah, Shahzad Maryam, Mahmmoud Fadelallah Eljack Mohammed

机构信息

Ayub Medical College, Abbottabad, Pakistan.

Dow University of Health Sciences, Karachi, Pakistan.

出版信息

Ann Med Surg (Lond). 2024 Oct 23;86(12):6916-6917. doi: 10.1097/MS9.0000000000002690. eCollection 2024 Dec.

DOI:10.1097/MS9.0000000000002690
PMID:39649856
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11623888/
Abstract
摘要